• 1. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 2. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 5. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Recent Advances in the Study of Methyl Imidazo[1,5-a]pyridine-1-carboxylate (CAS: 1039356-98-3)

Methyl imidazo[1,5-a]pyridine-1-carboxylate (CAS: 1039356-98-3) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. Recent studies have focused on its synthesis, structural modifications, and biological activities, particularly in the context of targeting specific enzymes and receptors involved in various diseases. This research brief aims to provide an overview of the latest findings related to this compound, highlighting its therapeutic potential and mechanistic insights.

One of the key areas of interest is the role of methyl imidazo[1,5-a]pyridine-1-carboxylate as a scaffold for designing novel kinase inhibitors. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is implicated in numerous diseases, including cancer and inflammatory disorders. Recent research has demonstrated that derivatives of this compound exhibit potent inhibitory activity against specific kinases, such as PI3K and mTOR, which are central to cell proliferation and survival. These findings suggest that methyl imidazo[1,5-a]pyridine-1-carboxylate could serve as a promising starting point for developing targeted therapies.

In addition to its kinase inhibitory properties, methyl imidazo[1,5-a]pyridine-1-carboxylate has been investigated for its potential as a modulator of G-protein-coupled receptors (GPCRs). GPCRs are a large family of membrane proteins involved in signal transduction and are important drug targets. Preliminary studies indicate that certain analogs of this compound can selectively bind to and activate or inhibit specific GPCRs, offering new avenues for treating neurological and metabolic disorders. Further optimization of these analogs could lead to the development of more efficacious and selective drugs.

The synthetic routes for methyl imidazo[1,5-a]pyridine-1-carboxylate and its derivatives have also been a focus of recent research. Advances in catalytic methods, such as transition metal-catalyzed cross-coupling reactions, have enabled more efficient and scalable synthesis of these compounds. These improvements are crucial for facilitating further biological evaluation and potential clinical translation. Additionally, computational modeling and structure-activity relationship (SAR) studies have provided valuable insights into the molecular interactions that underlie the compound's biological effects, guiding the design of next-generation derivatives.

Despite these promising developments, challenges remain in the optimization of methyl imidazo[1,5-a]pyridine-1-carboxylate-based compounds. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed to enhance their therapeutic potential. Ongoing research is exploring various strategies, including prodrug approaches and formulation technologies, to overcome these limitations. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to translate these findings into clinically viable treatments.

In conclusion, methyl imidazo[1,5-a]pyridine-1-carboxylate (CAS: 1039356-98-3) represents a versatile and promising scaffold in medicinal chemistry. Its ability to target kinases and GPCRs, combined with advances in synthetic methodologies, positions it as a valuable tool for drug discovery. Future studies should focus on refining its pharmacological properties and expanding its therapeutic applications, paving the way for novel treatments for a range of diseases.

• 119448-87-2(Ethyl imidazo[1,5-a]pyridine-1-carboxylate)
• 138891-57-3(Imidazo[1,5-a]pyridine-1-carboxylic acid, 3-methyl-, ethyl ester)
• 138891-64-2(Imidazo[1,5-a]quinoline-3-carboxylic acid)
• 141912-71-2(Methyl imidazo[1,5-a]pyridine-5-carboxylate)
• 1039356-95-0(methyl 3-formylimidazo[1,5-a]pyridine-1-carboxylate)
• 138891-51-7(Imidazo[1,5-A]pyridine-1-carboxylic acid)
• 1234616-18-2(methyl 1H-imidazo[4,5-c]pyridine-4-carboxylate)
• 136985-13-2(IMIDAZO[1,5-A]QUINOLINE-3-CARBOXYLIC ACID, METHYL ESTER)
• 136985-14-3(Imidazo[1,5-a]quinoline-3-carboxylic acid, 1-methyl-, methyl ester)
• 76292-67-6(Ethyl imidazo[1,5-a]pyridine-5-carboxylate)